Cargando…

The Effects of Low HER2/neu Expression on the Clinicopathological Characteristics of Triple-Negative Breast Cancer Patients

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer (BC), and its diagnosis is associated with negative expression of hormone receptors and HER2/neu. It consists of 10-20% of all BCs diagnosed. METHODS AND MATERIALS: This study focuses on three groups with differe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dehghani, Mehdi, Keshavarz, Pedram, Talei, Abdolrasoul, Akrami, Majid, Tahmasebi, Sedighe, Safaie, Akbar, Ghanbari, Maryam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798168/ https://www.ncbi.nlm.nih.gov/pubmed/33112563 http://dx.doi.org/10.31557/APJCP.2020.21.10.3027

Ejemplares similares

Determination of Oncologic Outcomes, Satisfaction, and Psychosocial Well-being in Patients with Breast Cancer after Oncoplastic and Conventional Breast Conserving Surgery
por: Tahmasebi, Sedighe, et al.
Publicado: (2022)

Do site and type of metastasis in breast cancer show a changing pattern with increased age? A cross comparison of clinicopathological characteristics between age groups
por: Akrami, Majid, et al.
Publicado: (2018)

Medullary Breast Carcinoma and Invasive Ductal Carcinoma: A Review Study
por: Zangouri, Vahid, et al.
Publicado: (2018)

Pseudoangiomatous stromal hyperplasia of the breast: A case report
por: Tahmasebi, Sedigheh, et al.
Publicado: (2022)

Introducing novel and comprehensive models for predicting recurrence in breast cancer using the group LASSO approach: are estimates of early and late recurrence different?
por: Akrami, Majid, et al.
Publicado: (2018)

Clinicopathological Characteristics and Her-2/neu Status in Chinese Patients with Uterine Papillary Serous Carcinoma
por: Ren, Yulan, et al.
Publicado: (2011)

Chronological changes and trend of breast cancer clinics and pathology among Iranian women during 22 years from the largest breast cancer registry in Iran
por: Tahmasebi, Sedigheh, et al.
Publicado: (2019)

How accurate is frozen section pathology compared to permanent pathology in detecting involved margins and lymph nodes in breast cancer?
por: Namdar, Zahra Mehdipour, et al.
Publicado: (2021)

Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
por: Li, Qingguo, et al.
Publicado: (2011)

Establishment and Characterization of a New Triple Negative Breast Cancer Cell Line from an Iranian Breast Cancer Tissue
por: Ghaderi, Farzaneh, et al.
Publicado: (2019)

Evaluation of HER2/neu Expression in High-Grade Endometrial Carcinoma and Its Clinicopathological Correlation
por: Sarmadi, Soheila, et al.
Publicado: (2019)

Intraoperative radiation therapy in non-breast cancer patients: A report of 26 cases from Shiraz, south of Iran
por: Akrami, Majid, et al.
Publicado: (2020)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

Cytoplasmic Her2/neu Immunohistochemical Staining in Breast Cancer; From a Molecular Point of View
por: Safaei, Akbar, et al.
Publicado: (2019)

Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients
por: Kattan, Joseph, et al.
Publicado: (2022)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Unusual Gastric Metastasis in Triple-Negative (Estrogen Receptor/Progesterone Receptor/HER2neu Negative) GATA-Binding Protein 3-Positive Breast Cancer
por: Baa, Annie Kanchan, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Intraoperative Frozen Section in Women with Breast Cancer: Evidence from South of Iran
por: Omidifar, Navid, et al.
Publicado: (2022)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study
por: Hussein, Israa A, et al.
Publicado: (2020)

HER2/neu-based vaccination with li-Key hybrid, GM-CSF immunoadjuvant and trastuzumab as a potent triple-negative breast cancer treatment
por: Zhou, Yihan
Publicado: (2023)

Intraoperative radiation therapy for early stage breast cancer
por: Zangouri, Vahid, et al.
Publicado: (2022)

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure
por: Kmieciak, Maciej, et al.
Publicado: (2011)

The expression of HER2/neu in patients with lung cancer and its associated factors
por: Lashkarizadeh, Mohammadreza, et al.
Publicado: (2023)

Ultrasound and Clinicopathological Characteristics of Triple Receptor-Negative Breast Cancers
por: Choi, Yoon Jung, et al.
Publicado: (2011)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Conflicts women with breast cancer face with: A qualitative study
por: Ghaemi, Seyyede Zahra, et al.
Publicado: (2019)

Explaining Perceived Priorities in Women with Breast Cancer: A Qualitative Study
por: Ghaemi, Seyede Zahra, et al.
Publicado: (2019)

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
por: Rhee, Jiyoung, et al.
Publicado: (2008)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_rbu6jjrrehm13f9cdg5dnp11bp